An increasing number of patients with metastatic colorectal cancer (mCRC) are able to
receive 3 or more lines of therapy. Treatments in this setting can include regorafenib (an oral …

Purpose To evaluate the safety and efficacy of three oxaliplatin and fluoropyrimidine
regimens, with or without bevacizumab, as first-line treatment for metastatic colorectal …

While surgery is the cornerstone treatment for early-stage colorectal cancer, chemotherapy
is the first treatment option for metastatic disease when tumor lesions are frequently not fully …

Background The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival
benefit in patients with previously treated metastatic colorectal cancer (CRC) …

Purpose Six randomized phase II and III trials have investigated the role of oxaliplatin (OX)
in combination with capecitabine (CAP) or infusional fluorouracil (FU) in metastatic …

The treatment of patients with metastatic colorectal cancer has changed dramatically over
recent years. The more optimal use of 5-fluorouracil (5-FU) in association with folinic acid …

Trifluridine/tipiracil (FTD/TPI) is an orally active formulation of trifluridine, a thymidine-based
nucleoside analog, and tipiracil hydrochloride, a thymidine phosphorylase inhibitor that …

4 Background: Trifluridine/tipiracil (FTD/TPI) plus bevacizumab (Bev) demonstrated
promising efficacy in a randomized phase 2 trial of heavily pretreated patients (pts) with …

Over the past decade treatment for metastatic colorectal cancer (mCRC) has advanced
beyond single-agent fluoropyrimidine use to include various cytotoxic combination regimens …

Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the evolution of cancer chemotherapy for patients with colorectal cancer. Discuss …